PneumoNP in the nanomedicine value chain
PneumoNP is a research project funded under the European Union’s Seventh Framework Programme, involving 11 teams, from 6 different countries. These partners will actively cooperate in the nanomedicine value chain as far as preclinical validation from 2014 to 2017.
The main objective of the project is the development of a theragnostic system for the treatment of resistant Gram-negative bacterial infections in lungs. A majority of international stakeholders from the healthcare sector agree that infections due to antibiotic resistant Gram-negative bacteria are one of the major issues currently affecting global health, largely due to a lack of effective antibiotic therapy for this type of infection. The PneumoNP team will therefore specifically focus its attention on the pathogen Klebsiella pneumoniae, a global cause of antibiotic resistant infections.
PneumoNP will generate:
- a new inhalable drug system composed of a nanotherapeutic system combining an antimicrobial peptide or active pharmaceutical ingredient (API) and a nanocarrier;
- a new aerosol technology specifically developed for the nanotherapeutic system;
- an innovative efficiency-efficacy test to follow-up the treatment;
- a new diagnostic kit for the rapid and multiplex identification of bacteria causing respiratory infections.
Find out how the PneumoNP work will be carried out and divided into work packages from 2014 to 2017.